Journal Mobile Options
Table of Contents
Vol. 72, No. 1, 2004
Issue release date: August 2004
Pharmacology 2004;72:1–5
(DOI:10.1159/000078625)

Efficacy of Donepezil Treatment in Alzheimer Patients with and without Subcortical Vascular Lesions

Blasko I. · Bodner T. · Knaus G. · Walch T. · Monsch A. · Hinterhuber H. · Marksteiner J.
aDepartment of Psychiatry, University Hospital of Innsbruck, Innsbruck, Austria, and bGeriatric University Hospital, Basel, Switzerland

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

In a pilot study designed as a case control study the efficacy of donepezil treatment was investigated in patients with Alzheimer’s disease (AD). Patients were stratified according to radiological criteria into patients without (AD group) and with subcortical vascular lesions (AD+SVD group). Changes in cognition were assessed as the primary outcome measurement after 6 and 18 months of treatment by the Mini-Mental Status Examination (MMSE) and the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) test battery. After 6 months, patients had improved from baseline by 0.7 points in MMSE score in the AD group and by 1.8 in the AD+SVD group. After 18 months of treatment, the AD+SVD group performed significantly worse in one CERAD subscore, whereas a deterioration in two subscores was observed in the AD group. A comparison between the 2 groups revealed that treatment did not lead to statistically significant differences between the AD and AD+SVD groups in any of CERAD parameters following 6 or 18 months of treatment. These data support previous observations that donepezil therapy is effective in AD patients with and without subcortical vascular lesions.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kalaria RN, Ballard C: Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S115–S123.
  2. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: A randomised trial. Lancet 2002;359:1283–1290.
  3. Meyer JS, Chowdhury MH, Xu G, Li YS, Quach M: Donepezil treatment of vascular dementia. Ann NY Acad Sci 2002;977:482–486.
  4. Pratt RD, Perdomo CA: Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann NY Acad Sci 2002;977:513–522.
  5. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R: Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323–2330.
  6. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD: Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology 2003;61:479–486.
  7. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925–926.
  8. Davis PB, Morris JC, Grant E: Brief screening tests versus clinical staging in senile dementia of the Alzheimer type. J Am Geriatr Soc 1990;38:129–135.
  9. Welsh K, Butters N, Hughes J, Mohs R, Heyman A: Detection of abnormal memory decline in mild cases of Alzheimer’s disease using CERAD neuropsychological measures. Arch Neurol 1991;48:278–281.
  10. Welsh KA, Butters N, Hughes JP, Mohs RC, Heyman A: Detection and staging of dementia in Alzheimer’s disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer’s Disease. Arch Neurol 1992;49:448–452.
  11. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994;44:609–614.
  12. Monsch AU: Neuropsychological examination in evaluating dementia (in German). Schweiz Rundsch Med Prax 1997;86:1340–1342.
  13. Berres M, Monsch AU, Bernasconi F, Thalmann B, Stahelin HB: Normal ranges of neuropsychological tests for the diagnosis of Alzheimer’s disease. Stud Health Technol Inform 2000;77:195–199.
  14. Folstein MF, Robins LN, Helzer JE: The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812.
  15. Scarpini E, Scheltens P, Feldman H: Treatment of Alzheimer’s disease: Current status and new perspectives. Lancet Neurol 2003;2:539–547.
  16. Schmidtke K, Hull M: Neuropsychological differentiation of small vessel disease, Alzheimer’s disease and mixed dementia. J Neurol Sci 2002;203–204:17–22.
  17. Tierney MC, Black SE, Szalai JP, Snow WG, Fisher RH, Nadon G, Chui HC: Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia. Arch Neurol 2001;58:1654–1659.
  18. Frolich L: The cholinergic pathology in Alzheimer’s disease – Discrepancies between clinical experience and pathophysiological findings. J Neural Transm 2002;109:1003–1013.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50